FDA Announces Draft Guidance for Chemotherapy-Induced Peripheral Neuropathy
January 18, 2025
January 18, 2025
WASHINGTON, Jan. 18 (TNSFR) -- The Food and Drug Administration (FDA) has released a draft guidance to support the development of drugs and biological products aimed at preventing and treating chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.
CIPN is a common side effect of neurotoxic chemotherapy treatments, often causing pain, disability, and the potential for irreversible nerve damage. This condition may lead to treatment disruptions, dose reductions, and pre . . .
CIPN is a common side effect of neurotoxic chemotherapy treatments, often causing pain, disability, and the potential for irreversible nerve damage. This condition may lead to treatment disruptions, dose reductions, and pre . . .